Literature DB >> 10359534

Methylation and silencing of the Thrombospondin-1 promoter in human cancer.

Q Li1, N Ahuja, P C Burger, J P Issa.   

Abstract

Neovascularization is a common feature of many human cancers, but relatively few molecular defects have been demonstrated in genes regulating angiogenesis. Decreased expression of Thrombospondin-1 (THBS1), a P53 and Rb regulated angiogenesis inhibitor, has been observed in some human tumors, including glioblastoma multiforme (GBM). To study whether methylation-associated inactivation is involved in down-regulating THBS1 expression in cancer, we analysed the methylation status of THBS1 in several cell lines and primary tumors. Three cell lines (RKO, CEM and RAJI) were completely methylated at several CpG sites within the THBS1 5' CpG island, and had no detectable expression by RT-PCR. THBS1 expression was readily reactivated using the methylation-inhibitor 5-deoxy-azacytidine in all three lines. Furthermore, THBS1 methylation was present in 33% (14/42) of primary GBMs. Thus, de novo methylation may serve as a potential way to inactivate THBS1 expression in human neoplasms.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10359534     DOI: 10.1038/sj.onc.1202663

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  34 in total

1.  Hemizygous deletion and hypermethylation of RUNX3 gene in hepatocellular carcinoma.

Authors:  Wen-Hua Xiao; Wei-Wen Liu
Journal:  World J Gastroenterol       Date:  2004-02-01       Impact factor: 5.742

2.  Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation.

Authors:  Yutaka Kondo; Lanlan Shen; Pearlly S Yan; Tim Hui-Ming Huang; Jean-Pierre J Issa
Journal:  Proc Natl Acad Sci U S A       Date:  2004-05-03       Impact factor: 11.205

3.  Activation of silenced tumor suppressor genes in prostate cancer cells by a novel energy restriction-mimetic agent.

Authors:  Hsiang-Yu Lin; Yi-Chiu Kuo; Yu-I Weng; I-Lu Lai; Tim H-M Huang; Shuan-Pei Lin; Dau-Ming Niu; Ching-Shih Chen
Journal:  Prostate       Date:  2012-04-26       Impact factor: 4.104

Review 4.  DNA Hypomethylating Drugs in Cancer Therapy.

Authors:  Takahiro Sato; Jean-Pierre J Issa; Patricia Kropf
Journal:  Cold Spring Harb Perspect Med       Date:  2017-05-01       Impact factor: 6.915

5.  The aberrant methylation of TSP1 suppresses TGF-beta1 activation in colorectal cancer.

Authors:  Andres Rojas; Shereen Meherem; Young-Ho Kim; Mary Kay Washington; Joseph E Willis; Sanford D Markowitz; William M Grady
Journal:  Int J Cancer       Date:  2008-07-01       Impact factor: 7.396

6.  Id1 overexpression is independent of repression and epigenetic silencing of tumor suppressor genes in melanoma.

Authors:  Megan A Healey; Staci L Deaton; Jonathan K Alder; Véronique Winnepenninckx; Robert A Casero; James G Herman
Journal:  Epigenetics       Date:  2010-07-01       Impact factor: 4.528

Review 7.  Animal models and the tumor microenvironment: studies of tumor-host symbiosis.

Authors:  Daniel Lindner
Journal:  Semin Oncol       Date:  2014-02-14       Impact factor: 4.929

8.  Methylation-specific multiplex ligation-dependent probe amplification identifies promoter methylation events associated with survival in glioblastoma.

Authors:  K L Rankeillor; D A Cairns; C Loughrey; S C Short; P Chumas; A Ismail; A Chakrabarty; S E Lawler; P Roberts
Journal:  J Neurooncol       Date:  2014-02-20       Impact factor: 4.130

9.  Thrombospondin-1 expression in melanoma is blocked by methylation and targeted reversal by 5-Aza-deoxycytidine suppresses angiogenesis.

Authors:  Daniel J Lindner; Yan Wu; Rebecca Haney; Barbara S Jacobs; John P Fruehauf; Ralph Tuthill; Ernest C Borden
Journal:  Matrix Biol       Date:  2012-11-30       Impact factor: 11.583

10.  Methylation of DAPK and THBS1 genes in esophageal gastric-type columnar metaplasia.

Authors:  Roberto Herrera-Goepfert; Luis F Oñate-Ocaña; José Luis Mosqueda-Vargas; Luis A Herrera; Clementina Castro; Julia Mendoza; Rodrigo González-Barrios
Journal:  World J Gastroenterol       Date:  2016-05-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.